Why Puma Biotechnology (PBYI) Stock Is Plunging Today

NEW YORK (TheStreet) -- Puma Biotechnology  (PBYI) plunged Monday after GlaxoSmithKline  (GSK) announced its drug Tykerb, designed to treat adjuvant breast cancer, missed its primary endpoint in a Phase III trial. 

Puma is also trying to develop a breast cancer drug, PB272, for the treatment of HER2 positive metastatic breast cancer. The company actually reported positive results from its ongoing Phase II clinical trial of its experimental drug to treat breast cancer that has metastasized to the brain, but the GlaxoSmithKline news sent the stock plummeting.

The stock was down 21.14% to $60.27 at 11:22 a.m.

Must Read: Warren Buffett's 25 Favorite Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

PBYI Price Chart

PBYI Price data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Dow Ends Off 125 Points as Caterpillar, 3M Earnings Disappoint

Dow Ends Off 125 Points as Caterpillar, 3M Earnings Disappoint

Multiple Tailwinds Take Shape That Could Drive BP Gains

Multiple Tailwinds Take Shape That Could Drive BP Gains

Tesla Critic Citron Research Changes Its Mind, Goes Long on the EV Maker

Tesla Critic Citron Research Changes Its Mind, Goes Long on the EV Maker

Verizon Beats Q3 Earnings Estimate, Postpaid Phone Additions Top Forecasts

Verizon Beats Q3 Earnings Estimate, Postpaid Phone Additions Top Forecasts

Philip Morris Rolls Out New Smokeless Cigs to Fire Up Sales

Philip Morris Rolls Out New Smokeless Cigs to Fire Up Sales